Propanc Biopharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	18.07	57.05	1.29	1.53	1.73	1.58
Research & Development	0.3	0.22	0.25	0.25	0.26	0.23
Total Operating Expenses	18.37	57.28	1.54	1.78	1.99	1.81
Operating Income	-18.37	-57.28	-1.54	-1.78	-1.99	-1.81
Interest Income	-0.06	0	0	0	0.01	0
Interest Expense	-0.66	-0.56	-0.67	-0.53	-0.57	-0.45
Other Non-Operating Income (Expense)	0.67	-1.08	0.25	-0.48	-0.16	0.12
Total Non-Operating Income (Expense)	-0.05	-1.65	-0.41	-1.01	-0.72	-0.33
Pretax Income	-18.36	-58.92	-1.95	-2.79	-2.71	-2.14
Provision for Income Taxes	-	-	-0.13	-0.13	-0.05	-0.11
Net Income	-19.29	-58.92	-2.01	-3.13	-3.36	-2.42
Net Income Attributable to Preferred Dividends	0.93	-	0.19	0.47	0.7	0.39
Net Income to Common	-19.29	-58.92	-2.01	-3.13	-3.36	-2.42
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	1272.09%	279940.58%	4789.58%	2448.85%	2149.51%	12210.64%
EPS (Basic)	570.00	-371.25	-35513.30	-2700000.00	-73845000.00	-1200000000.00
EPS (Diluted)	570.00	-371.25	-35513.30	-2700000.00	-73845000.00	-1200000000.00
EPS Growth	-98.63%	-	-	-	-	-
Shares Outstanding	0.87	0.46	0	0	0	-
Free Cash Flow	-4.18	-0.41	-0.94	-1.11	-1.44	-1.15
Free Cash Flow Per Share	-6.99	-2.55	-16498.20	-953459.00	-31581500.00	-566474000.00
EBITDA	-18.37	-57.28	-1.54	-1.77	-1.99	-1.81
EBIT	-18.37	-57.28	-1.54	-1.78	-1.99	-1.81
Effective Tax Rate	-	0.00%	6.62%	4.65%	2.03%	5.30%